Health LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026 November 6, 2026
Health Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) November 6, 2026
Health Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook November 5, 2026
Health Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer November 5, 2026